Skip to main content

University of Exeter Medical School

Dr Katie Young

Dr Katie Young

Research Fellow

 K.Young3@exeter.ac.uk

 RILD Building 3.03

 

University of Exeter Medical School, RILD Building, RD&E Hospital Wonford, Barrack Road, Exeter, EX2 5DW, UK


Overview

Katie is a Research Fellow in Health Data Science, working in Professor Andrew Hattersley’s clinical diabetes research team.

Previously Katie worked as a Research Data Coordinator within the team, using data from UK Biobank (particularly primary care records) to identify prevalent and incident cases of diabetes.

In her current role she is working with primary care data from the Clinical Practice Research Datalink (CPRD): developing reproducible pipelines for defining diabetes cohort, and contributing to work on stratified medicine in Type 2 diabetes (with Dr John Dennis) and diabetes misclassification in primary care (with Dr Beverley Shields).

Qualifications

  • PhD in Biophysics (University of Oxford)
  • MBiochem Biochemistry (University of Oxford)

Back to top


Research

Research interests

  • Primary care record usage in research
  • Type 2 diabetes
  • Stratified / personalised medicine
  • Diabetes misclassification

Back to top


Publications

Journal articles

McKinley T, Cardoso P, Dennis J, Young K, Hopkins R, McGovern A, Bowden J, Hattersley A, Jones A, Shields B, et al (In Press). Phenotype-based targeted treatment of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes. Diabetologia
Hopkins R, Young K, Thomas N, Godwin J, Raja D, Mateen B, Challen R, Vollmer S, Shields B, McGovern A, et al (In Press). Risk factor associations for severe Covid-19, influenza, and pneumonia in people with diabetes to inform future pandemic preparations: UK population-based cohort study. BMJ Open
Black N, Chung S, Tisdale C, Fialho LS, Aramrattana A, Assanangkornchai S, Blaszczynski A, Bowden-Jones H, van den Brink W, Brown A, et al (2024). An International, Multidisciplinary Consensus Set of Patient-Centered Outcome Measures for Substance-Related and Addictive Disorders. J Clin Med, 13(7). Abstract.  Author URL.
Young KG, Dennis JM, Thomas NJM (2024). Challenges of detecting childhood diabetes in primary care. The Lancet Digital Health, 6(6), e375-e376.
Young KG, McGovern AP, Barroso I, Hattersley AT, Jones AG, Shields BM, Thomas NJ, Dennis JM (2023). HbA1c screening for the diagnosis of diabetes. Reply to Brož J, Brabec M, Krollová P et al [letter]. Diabetologia, 66(8), 1578-1579.  Author URL.
Young KG, McInnes EH, Massey RJ, Kahkohska AR, Pilla SJ, Raghaven S, Stanislawski MA, Tobias DK, McGovern AP, Dawed AY, et al (2023). Precision medicine in type 2 diabetes: a systematic review of treatment effect heterogeneity for GLP1-receptor agonists and SGLT2-inhibitors. Abstract.
Young KG, Hopkins R, Shields BM, Thomas NJ, McGovern AP, Dennis JM (2023). Recent UK type 2 diabetes treatment guidance represents a near whole population indication for SGLT2-inhibitor therapy. Abstract.
Tobias DK, Merino J, Ahmad A, Aiken C, Benham JL, Bodhini D, Clark AL, Colclough K, Corcoy R, Cromer SJ, et al (2023). Second international consensus report on gaps and opportunities for the clinical translation of precision diabetes medicine. Nature Medicine, 29(10), 2438-2457.
Young KG, McGovern AP, Barroso I, Hattersley AT, Jones AG, Shields BM, Thomas NJ, Dennis JM (2023). The impact of population-level HbA1c screening on reducing diabetes diagnostic delay in middle-aged adults: a UK Biobank analysis. Diabetologia, 66(2), 300-309. Abstract.  Author URL.
Dennis JM, Young KG, McGovern AP, Mateen BA, Vollmer SJ, Simpson MD, Henley WE, Holman RR, Sattar N, Pearson ER, et al (2022). Development of a treatment selection algorithm for SGLT2 and DPP-4 inhibitor therapies in people with type 2 diabetes: a retrospective cohort study. The Lancet Digital Health, 4(12), e873-e883.
Thomas NJ, McGovern A, Young KG, Sharp SA, Weedon MN, Hattersley AT, Dennis J, Jones AG (2022). Identifying type 1 and 2 diabetes in research datasets where classification biomarkers are unavailable: assessing the accuracy of published approaches. Journal of Clinical Epidemiology, 153, 34-44.
Gilchrist M, Casanova F, Tyrrell JS, Cannon S, Wood AR, Fife N, Young K, Oram RA, Weedon MN (2022). Prevalence of Fabry disease-causing variants in the UK Biobank. Journal of Medical Genetics, 60(4), 391-396. Abstract.
Heald AH, Martin S, Fachim H, Green HD, Young KG, Malipatil N, Siddals K, Cortes G, Tyrrell J, Wood AR, et al (2021). Genetically defined favourable adiposity is not associated with a clinically meaningful difference in clinical course in people with type 2 diabetes but does associate with a favourable metabolic profile. Diabetic Medicine, 38(9). Abstract.
Young KG, McDonald TJ, Shields BM (2021). Glycated haemoglobin measurements from UK Biobank are different to those in linked primary care records: implications for combining biochemistry data from research studies and routine clinical care. Abstract.
Young KG, Najafi B, Sant WM, Contera S, Louis AA, Doye JPK, Turberfield AJ, Bath J (2020). Reconfigurable T‐junction DNA Origami. Angewandte Chemie, 132(37), 16076-16080.

Conferences

Young KG, Hopkins R, Thomas NJ, Shields BM, Dennis JM, McGovern AP (2022). Current rates of sodium-glucose link transporter 2 inhibitors (SGLT2i) prescribing in type 2 diabetes show no evidence of prioritisation in those with cardiovascular disease and heart failure.  Author URL.
Hopkins R, Godwin J, Young KG, Mateen BA, Vollmer SJ, Thomas NJ, Shields BM, McGovern AP, Dennis JM (2022). In people with type 2 diabetes most risk factors for covid-19 mortality are shared with pneumonia, however ethnicity related risk is very different.  Author URL.
Hopkins R, Young KG, Godwin J, Raja D, Thomas NJ, Shields BM, Dennis JM, McGovern AP (2022). Modifiable risk factors including HbA<sub>1c</sub> and BMI are consistently associated with severe influenza, pneumonia, and Covid-19 infection outcomes in people with type 2 diabetes.  Author URL.
Young KG, McGovern AP, Hopkins R, Raya D, Sattar NA, Holman RR, Pearson ER, Hattersley AT, Jones AG, Shields BM, et al (2022). Precision medicine in type 2 diabetes: integrating trial and real-world evidence can provide accurate estimates of heart failure benefit when initiating SGLT2-inhibitors.  Author URL.
Tyrrell J, Gillett A, Casanova F, Young K, Green H, Lewis C, Hagenaars S (2022). The impact of depression. diagnosis on diabetes and lifetime hyperglycaemia. World Congress of Psychiatric Genetic (WCPG). 13th - 17th Sep 2022.
Gilchrist M, Casanova F, Tyrrell J, Fife N, Young K, Oram R, Weedon M (2021). MO042PREVALENCE OF FABRY DISEASE CAUSING VARIANTS IN THE UK BIOBANK. Abstract.
Young KG, Dennis JM, Thomas NJ, Jones AG, McGovern A, Shields BM, Barroso I, Hattersley AT (2021). Participants with undiagnosed diabetes in UK Biobank wait on average two years to receive a diagnosis, and simple clinical features are associated with diagnosis delays.  Author URL.
Carr ALJ, Sharp SA, Young KG, Thomas NJ, Hattersley AT, Jones AG, Oram RA (2020). A type 1 diabetes genetic risk score is discriminative of adult-onset type 1 diabetes.  Author URL.
Young KG, Hill A, Tippett P, Knight BA, Hattersley AT, McDonald T, Shields BM, Thomas NJ, Jones AG (2020). Adult-onset autoimmune diabetes has similar markers of severity and progression regardless of age of diagnosis, but is less likely to be managed intensively when diagnosed in older adults.  Author URL.
Young KG, Thomas NJ, Jones AG, McGovern A, Shields BM, Barroso I, Hattersley AT (2020). HbA<sub>1c</sub> screening in 195,460 'non-diabetic' individuals (40-69 years) identifies 1.1% with undiagnosed diabetes 2 years before clinical diagnosis.  Author URL.
Young K, Najafi B, Bath J, Turberfield A (2017). DNA T-junctions for studies of DNA origami assembly.

Back to top


Edit Profile